Back
HuagongsheHuagongshe Chemistry Print Report · For research reference only
HRID 931998Generated: October 29, 2026

Acetone → 2-((3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-((S)-1-morpholinobutan-2-yl)-2-oxopiperidin-3-yl)acetic acid

https://huagongshe.com/reaction/931998

Reaction equation

Participants

RoleNameHCIDCharge
ReactantAcetoneHCID 180—
Reactant2-((3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-((S)-1-morpholinobutan-2-yl)-2-oxopiperidin-3-yl)acetaldehydeHCID 58573581—
SolventWaterHCID 962—
SolventSulfuric AcidHCID 1118—
SolventEthyl AcetateHCID 8857—
Product2-((3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-((S)-1-morpholinobutan-2-yl)-2-oxopiperidin-3-yl)acetic acidHCID 58573557—

Reaction Steps

To a solution of 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-((S)-1-morpholinobutan-2-yl)-2-oxopiperidin-3-yl)acetaldehyde (Example 91, Step E) (125 mg, 0.242 mmol) in acetone (2 mL) was added 3 mL of a mixture of CrO3 in water (2 mL) and concentrated H2SO4 (1 ml). The reaction mixture was stirred at room temperature for 2 hours and then diluted with water (10 mL) and ethyl acetate (10 mL) and the layers were separated. The aqueous layer was extracted with additional ethyl acetate (10 mL). The combined organic layers were concentrated under reduced pressure. The residue was purified by reversed phase preparatory HPLC (column: Gemini-NX C18 5 um column; Phenomonex, Torrance, Calif.; eluent: 0 to 100% MeCN +0.1% TFA in water +0.1% TFA) to provide the title compound.

Provenance & Evidence

DOI10.6084/m9.figshare.5104873.v1
Patent numberUS09296736B2
Source datasetuspto-grants-2016_03
ORD IDord-ea2622a89b914ce3b8a47faeff1d8e9d
Source noteuspto-grants-2016_03